Epidermal Growth Factor Receptor Inhibition in the Management of Squamous Cell Carcinoma of the Lung

• Published in: The oncologist (Dayton, Ohio) Ohio), 2016-02, Vol.21 (2), p.205-213
• Main Authors: Goss, Glenwood D., Spaans, Johanna N.
• Format: Article
• Language: English
• Subjects: Antineoplastic Agents - administration & dosage; Antineoplastic Agents - adverse effects; Carcinoma, Non-Small-Cell Lung - drug therapy; Carcinoma, Non-Small-Cell Lung - genetics; Carcinoma, Non-Small-Cell Lung - pathology; Combined Modality Therapy; Disease-Free Survival; Epidermal growth factor receptor; ErbB Receptors - antagonists & inhibitors; ErbB Receptors - genetics; Humans; Induction Chemotherapy; Lung Cancer; Meta‐analysis; Molecular Targeted Therapy; Monoclonal antibodies; Mutation; Non‐small cell lung cancer; Protein Kinase Inhibitors - administration & dosage; Protein Kinase Inhibitors - adverse effects; Small molecule; Squamous
• ISSN: 1083-7159; 1549-490X
• DOI: 10.1634/theoncologist.2015-0209

Molecular therapies targeting epidermal growth factor receptor (EGFR) have had a profound impact on the management of advanced non‐small cell lung cancer (NSCLC). EGFR inhibition with EGFR tyrosine kinase inhibitors (EGFR‐TKIs) and anti‐EGFR monoclonal antibodies (mAbs) in squamous NSCLC (sqNSCLC) remains controversial in patients whose tumors are not known to harbor EGFR mutations. Recent meta‐analyses of EGFR‐inhibition randomized trials that are adequately powered for histological subgroup analysis and anti‐EGFR trials limited to patients with squamous histology afford the opportunity to revisit EGFR treatment in sqNSCLC. In unselected patients with sqNSCLC who are not eligible for chemotherapy, EGFR‐TKI therapy is a valid treatment option over placebo or best supportive care, with improved progression‐free survival noted in randomized controlled trials in both the first‐ and second‐line setting and improved overall survival (OS) in the second‐line setting. In patients eligible for chemotherapy, first‐line combination regimens with anti‐EGFR mAbs have been shown to improve OS over chemotherapy alone in patients with squamous histology in meta‐analysis and more recently in the SQUIRE sqNSCLC trial (chemotherapy with and without necitumumab). In sqNSCLC patients who respond to induction chemotherapy, maintenance therapy with erlotinib delays disease progression and may improve the survival of patients with stable disease. In the second‐line setting, survival outcomes are comparable between chemotherapy and EGFR‐TKIs in meta‐analysis, with the latter being more tolerable as a second‐line therapy. Newer‐generation EGFR‐TKI therapies may further benefit patients with sqNSCLC who have failed first‐line chemotherapy, given the positive trial results from LUX‐Lung 8 (afatinib vs. erlotinib). EGFR is a valid therapeutic target in unselected/EGFR wild‐type patients with squamous cell carcinoma of the lung. With the recent approval of immune checkpoint inhibitors in the second‐line management of advanced sqNSCLC and their adoption as a new standard of care, there exists an opportunity for novel combination therapies to increase therapeutic efficacy and durable tumor control. As more targeted agents are approved, combination regimens that include an anti‐EGFR agent should be evaluated, and the optimal sequencing of targeted therapies should be defined. Implications for Practice: Anti‐epidermal growth factor receptor (EGFR) therapies remain controversial in unselect